Mitoxantrone

Historical note and nomenclature
Article section 1 of 12.  Next

By K K Jain MD

Mitoxantrone was first approved in 1986 for the treatment of acute myelogenous leukemia. In 1996 it was approved to treat pain in patients with advanced hormone-refractory prostate cancer in combination with corticosteroids. In 1997, results of clinical trials were published, describing the potential of mitoxantrone in treating patients with progressive multiple sclerosis; it was approved by the Food and Drug Administration for this indication in 2000.